Bone Loss
Bone Loss
CROI 2017: Bone Density Improves in People Who Switch from Tenofovir DF to Tenofovir Alafenamide
- Details
- Category: Bone Loss
- Published on Thursday, 16 March 2017 00:00
- Written by Liz Highleyman
After 3 years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir disoproxil fumarate (TDF), researchers reported at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. Another study showed that people with low bone density who switched from TDF to TAF saw improved bone health, including a reduction in osteoporosis.
CROI 2016: Tenofovir HIV Treatment Raises Risk of Broken Bones
- Details
- Category: Bone Loss
- Published on Tuesday, 23 February 2016 00:00
- Written by Keith Alcorn
Treatment containing tenofovir is associated with a higher risk of bone fractures in people living with HIV, but a single infusion of zoledronic acid -- a drug used in the treatment of osteoporosis -- can protect against bone loss, a pair of studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) this week in Boston show.
IAS 2015: Bone Loss Slows, but Continues Long-term in HIV-positive People on Antiretroviral Therapy
- Details
- Category: Bone Loss
- Published on Wednesday, 09 September 2015 00:00
- Written by Liz Highleyman
People with HIV experienced a decrease in bone density at the hip and spine during their first 2 years after starting antiretroviral therapy (ART). While bone loss slowed after 96 weeks, it continued to decline more rapidly among HIV-positive people compared with the usual age-related bone loss seen in HIV-negative people over 7 years, researchers reported at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
CROI 2016: Bone Density Recovers Quickly After Stopping Truvada PrEP
- Details
- Category: Bone Loss
- Published on Tuesday, 23 February 2016 00:00
- Written by Keith Alcorn
Bone mineral density recovers within 6 months after stopping pre-exposure prophylaxis (PrEP) containing tenofovir, Robert Grant from the University of California at San Francisco reported on behalf of the iPrEx study at Conference on Retroviruses and Opportunistic Infections (CROI 2016) this week in Boston.
CROI 2015: FRAX Fracture Prediction Tool Underestimates Fracture Risk in Men with HIV
- Details
- Category: Bone Loss
- Published on Tuesday, 17 March 2015 00:00
- Written by Theo Smart
The Fracture Risk Assessment Tool (FRAX), an online tool developed by the World Health Organization and used to help guide decisions about who to screen or treat in order to prevent bone fractures, underestimates overall risk of fracture in people living with HIV -- even with an adjustment experts have recommended to improve its accuracy for people with HIV -- according to an analysis of the Veterans Aging Cohort Study Virtual Cohort (VACS-VC) reported at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Web Design and Development by